Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Seasonal Allergic Rhinitis Pipeline Review, H2 2016 - Analysis, Technologies & Forecasts - Key Vendors: Allergy Therapeutics, Faes Farma, Pfizer - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Seasonal Allergic Rhinitis - Pipeline Review, H2 2016" drug pipelines to their offering.

The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seasonal Allergic Rhinitis and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The report provides a snapshot of the global therapeutic landscape of Seasonal Allergic Rhinitis
  • The report reviews pipeline therapeutics for Seasonal Allergic Rhinitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Seasonal Allergic Rhinitis therapeutics and enlists all their major and minor projects
  • The report assesses Seasonal Allergic Rhinitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Seasonal Allergic Rhinitis

Companies Mentioned:

  • Allergy Therapeutics Plc
  • Faes Farma, S.A.
  • Glenmark Pharmaceuticals Ltd.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • VentiRx Pharmaceuticals, Inc.

For more information about this drug pipelines report visit

Related Topics: Immune Disorders Drugs, Allergy Drugs

View source version on

Business Wire

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.